$CADX News
Last published 5y ago
- 5y agoARQTPASGPHATRXDX+1Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening LeadershipBusiness WireEleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertis
- 5y agoAMAMIBRXCADXAmbrx Appoints Sonja Nelson as Chief Financial OfficerBusiness WireAmbrx (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointment of Sonja Nelson to Chief Financial Officer. "I am delighted
- 12y agoMNKCADXMallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.Business WireDUBLIN--(BUSINESS WIRE)--Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion. As previously disclosed, Mallinckrodt expects that the acquisition will be immediately accretive to its fiscal year 2014 adjusted d ...
- 12y agoCADXSHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc. in Connection With the Sale of the Company to Mallinckrodt plcBusiness WireBALA CYNWYD, Pa.--(BUSINESS WIRE)--Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc (“MNK”).
- 12y agoCADXSHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc.Business WireBALA CYNWYD, Pa.--(BUSINESS WIRE)--Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc (“MNK”).
- 12y agoCADXMNKLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Cadence Pharmaceuticals, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (NASDAQ: CADX) concerning the proposed acquisition of the Company by Mallinckrodt plc (“Mallinckrodt”) (NYSE: MNK). Under the terms of the definitive merger agreement, Cadence stockholders will receive $14.00 in cash for each ...
- 12y agoMNKCADXMallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in CashBusiness WireDUBLIN & SAN DIEGO--(BUSINESS WIRE)--Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in ...